

CURIGRAFT[®] VIABLE ALLOGENIC BONE MATRIX

Features & Benefits




CURIGRAFT[®] Viable Allogenic Bone Matrix

CuriGraft Viable Allogenic Bone Matrix is the next generation solution for bone formation to support a variety of potential clinical applications. A natural, 100% tissue scaffold of demineralized cortical bone fibers coupled with chips rich with endogenous bone cells, provides an optimal microenvironment for osteogenesis and excellent handling. The allograft is packaged in an easy-to-use syringe with minimal preparation time of under 15 minutes. The endogenous bone cells are preserved in a DMSO-free (free of dimethyl sulfoxide) cryoprotectant, requiring no rinsing or decanting – just thaw and use.

Three Key Elements for Bone Formation

- An **osteoconductive** three-dimensional scaffold with cortical and cancellous components.
- A demineralized cortical bone scaffold. Demineralized cortical bone has been identified to have **osteoinductive potential**.¹
- Viable endogenous bone cells to support **osteogenic** healing processes.



Features and Benefits

- 100% human-derived product that mimics the particulate structure of native bone.
- Novel DMSO-free cryoprotectant preserving allograft and preventing crack propagation and membrane lysis²
 - Reduces concerns about cytotoxicity and negative effects on cell differentiation^{3,4,5}
 - No rinsing or decanting steps required
- Average cell viability exceeds 92% post-thaw²
- Average of 1.5 million viable cells per cc of allograft²
- Four-hour working window for implantation after thaw without loss of cell viability²

Product Code	Product Description
C034-0001-MCBMV	CuriGraft Viable Allogenic Bone Matrix, 1cc
C034-0025-MCBMV	CuriGraft Viable Allogenic Bone Matrix, 2.5cc
C034-0005-MCBMV	CuriGraft Viable Allogenic Bone Matrix, 5cc
C034-0010-MCBMV	CuriGraft Viable Allogenic Bone Matrix, 10cc



For more information or to place an order call: 877.9CURITEVA,
email: customersupport@curiteva.com or visit www.curiteva.com

1. Gruskin, E. et al., Demineralized bone matrix in bone repair: history and use. *Advanced Drug Delivery Reviews*, 2012. 64:1063-1077
 2. Data on file at Vivex Biologics, Inc.
 3. Best, Benjamin. P. Cryoprotectant Toxicity: Facts, Issues, and Questions. *Rejuvenation Research*, 2015. Vol. 18, No. 5.
 4. Renzi, S., et al., Mesenchymal stromal cell cryopreservation. *Biopreservation and Biobanking*, 2012. 10(3): p. 276-281.
 5. Asghar, W., et al., Preserving human cells for regenerative, reproductive, and transfusion medicine. *Biotechnology Journal*, 2014. 9: p. 895-903.



Copyright©2022 by Curiteva, Inc.
QMSF-1227 Rev 2.0